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Background: To compare the outcome of IVF cycles in women receiving controlled ovarian stimulation with
recFSH or recFSH plus low dose hCG.
Methods: A retrospective case control study, performed at a private practice affiliated with an academic institute.
Patients were infertile women who were treated with IVF/ICSI and controlled ovarian stimulation in a long GnRH
agonist protocol using either low dose hCG in addition to recFSH [N = 88] or recFSH alone [N = 99]. Primary
outcomes were mean FSH dose, number of mature eggs, number of fertilized eggs, and serum levels of estradiol.
Secondary outcomes were endometrial thickness, cycle cancellations and pregnancy rates.
Results: A significant increase in number of mature and fertilized eggs was observed in women over 40 years of
age using low dose hCG in addition to recFSH. The estradiol level was significantly higher on the day of hCG
administration and the serum level of FSH on cycle day 7 and on the day of hCG administration were lower.
Conclusion: Addition of low dose hCG to recFSH compared with recFSH alone significantly modified cycle
characteristics in patients >/= 40 years and could be of potential benefit for IVF cycles in older infertile women.
Keywords: Low dose hCG, In vitro fertilization, Ovarian stimulation, Oocyte maturation, Cost of treatmentBackground
Major advancements have been made in the treatment
of infertility over the past three decades. Multiple trials
have been conducted in order to achieve safe, effective,
and low cost treatment protocol for controlled ovarian
stimulation (COS) in patients undergoing IVF/ICSI. Des-
pite these developments, the age of the female patient is
still considered the most important prognostic factor for
both response to COS and for pregnancy outcome [1,2].
The most important hormone in the stimulation of
ovarian folliculogenesis is FSH [3]. There is controversy
about the importance of luteinizing hormone (LH) in
ovarian stimulation, although some studies have shown
that LH may improve ovarian response, in particular for
older women [4]. Another study showed that the use of
recLH in GnRH antagonist cycles improved the implant-
ation rate in older patients [5]. This beneficial effect was* Correspondence: ybentov@tcart.ca
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reproduction in any medium, provided the ornot seen with a microdose flare protocol [6]. The select-
ive contribution of LH to the outcome of IVF treatment
in older patients, has also been validated in a Cochrane
meta-analysis [7].
LH and hCG share structural similarities and function
through the same receptor [8]. The half-life of hCG is
longer (2.32 days) than LH which has a half-life esti-
mated to be about 1 hour [9]. In addition, hCG has
stronger LH receptor binding affinity than LH [10] and
has, therefore, been used as a substitute for LH [11]. It
is administered at doses of 5.000-10.000 IU to mimic the
endogenous LH surge and to achieve oocyte maturation
and release of the cumulus-oocyte complex.
Drakakis at al demonstrated the superiority of hCG
over recLH as an adjuvant to recFSH in the first four
days of ovarian stimulation. The use of hCG resulted in
a higher number of follicles, oocytes, peak estradiol and
number of transferable embryos [11].
Filicori and colleagues demonstrated that low dose
hCG can be used clinically to replace FSH to complete
controlled ovarian stimulation in a long GnRH agonist
protocol [12]. Following pituitary downregulation andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tinued and stimulation was continued with 200 IU of
hCG only. The outcome of the treatment was compar-
able to the control group that was treated with recFSH
throughout the cycle. Similar findings were described
also in GnRH antagonist cycles, in which, low dose hCG
replaced recFSH in the final days of stimulation with a
comparable outcome [13]. The addition of low doses of
hCG to FSH in a long stimulation protocol in PCOS
patients improved mature oocyte yield at lower cost and
avoided OHSS, without a drop in pregnancy rates [14].
It has also been shown that the addition of hCG prior to
FSH stimulation (hCG priming) may have a positive ef-
fect on oocyte maturity in controlled ovarian stimulation
[15].
The aim of the present study was to evaluate the im-
pact of low dose hCG as a supplement to recFSH for
ovarian stimulation as part of a long GnRH agonist
protocol in IVF patients. We examined the clinical out-
come and the cost-effectiveness of this protocol in
women <40 or ≥ 40 years of age.
Methods
The study was a retrospective case–control study, con-
ducted at the Toronto Center for Advanced Reproduct-
ive Technology, a University of Toronto affiliated private
practice. The study was approved by the institutional
ethics committee.
In this study we collected and analyzed data of 187
IVF/ICSI cycles conducted between January 2010 and
November 2011. We allocated patients to two main
groups according to the use of hCG as part of their IVF
stimulation. Group 1 included 88 patients who received
low dose hCG in conjunction with recFSH and Group 2
included 99 patients who received recFSH only for
stimulation. Each group was subdivided by age to A (less
than 40 years-old) and B (40 years or older).
Women in both groups were treated with a long
GnRH agonist protocol (buserelin, Suprefact, Hoechst,
Frankfurt, Germany) and received recFSH injections
(GonalF, Serono, Canada or Puregon, Organon, Canada)
from cycle day 3, and injection of 10.000 IU of hCG was
given to all patients to trigger ovulation when the appro-
priate number of mature follicles was visualized. The ini-
tial dose of FSH was based on each patient’s clinical
condition and her response in previous treatment cycles
if available; the dose was then adjusted according to the
patient response. Cycle monitoring was conducted by
transvaginal ultrasound and serial hormonal profiles in-
cluding FSH, LH, E2 and progesterone starting from
CD3 of the stimulated cycle until the day of the hCG
trigger.
In Group 1, low dose hCG (200 IU per day) was
started on cycle day 3 until the day of the hCG triggeradministration. Group 2 patients received recFSH injec-
tions alone starting on cycle day 3 of the stimulation
cycle until the day of hCG trigger administration. Stimu-
lation regimens were selected as per physician prefer-
ence. There were no specific criteria used to determine
the stimulation protocol. Oocytes were retrieved 36 h
after the hCG trigger shot. All mature eggs retrieved
were fertilized with either standard IVF or intracytoplas-
mic sperm injection (ICSI). Fertilization was checked at
18 hours post insemination. Embryo quality was assessed
daily.
The number of embryos transferred was based on day
of transfer, age of the patient and quality of embryos
according to 2009 SART/ASRM (American Society of
Reproductive Medicine) guidelines for the number of
embryos transferred [16]. Luteal phase support consisted
of progesterone vaginal suppositories 200 mg 3 times
daily. Serum beta hCG measurement was done 14 days
after egg retrieval and if positive, it was repeated 48
hours later. Clinical pregnancy was confirmed by ultra-
sound at 6-8 weeks of pregnancy.
We collected and analyzed the clinical data of patients
in both groups including age, cause and duration of in-
fertility, number of previous cycles and cancelled cycles
and cause of cancellation. We also calculated the total
dose of FSH given throughout the cycle.
The primary outcome measures were the dose of FSH
needed, the number of mature eggs, the cost per mature
egg, the number of fertilized eggs, and serum level of es-
tradiol (E2). Secondary outcomes were endometrial
thickness on the day of hCG administration, cycle can-
cellations and the pregnancy rate.
Statistical analysis
Data were collected and tabulated using 2007 Microsoft
office system - Excel version (Microsoft Corporation),
expressed as mean + -SD and analyzed using student’s
t-test.
Results
We compared patients younger than 40 years old using
low dose hCG (Group 1-A) to using recFSH (Group 2-A)
and patients 40 years or older using low dose hCG
(Group 1-B) to using recFSH alone (Group 2-B). Each
groups had comparable baseline features at the start of
the cycle including mean age, BMI, indication for treat-
ment, method of fertilization and semen parameters and
baseline hormonal profile (table 1).
The number of cancelled cycles was almost the same in
both groups. There were three cancelled cycles in group
1-A, two because of poor response and one at patient re-
quest. There were two cancelled cycles in group 2-A be-
cause of poor response. There were no cancelled cycles in
group 1-B and four cancelled cycles in group 2-B because







P Value Group 1-B r
FSH+ Low dose





Age (Mean± SD) years old 35.86 ± 2.95 34.90 ± 3.23 42.00 ± 1.02 41.57 ± 0.99








LMA+Male factor 9 6
LMA+ Endometriosis 3 2
LMA+ Tubal 4 5
Semen Concentration 27.36 ± 23.19 27.12 ± 28.40 0.481 28.82 ± 28.26 26.04 ± 23.75 0.333
Insemination Method
IVF 14 11 6 5
ICSI 27 48 32 22
IVF/IVSI 4 6
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responders if less than three follicles developed.
We found no significant differences in the hormonal
profiles on any cycle day (Table 2), total dose of FSH
used, number of mature eggs, and number of fertilized
eggs in the women under the age of 40 years (Table 3).
In group1-A, there were no cases of ovarian hyper-
stimulation syndrome (OHSS) compared to 5 cases
recorded in group 2-A. All cases of OHSS were mild toTable 2 Hormonal profile and ultrasound measurements in tr
Group 1-A r





CD3 FSH (IU/L) 5.38 ± 2.61 5.78 ± 3.26
CD3 LH (IU/L) 3.55 ± 2.61 3.67 ± 0.58
CD3 E2 (pmol/L) 112.23 ± 131.99 114.73 ± 51.89
CD 3 Progesterone (nmol/L) 4.13 ± 2.42 3.33 ± 2.23
FSH (IU/ML) on day
of HCG admin
13.35 ± 5.14 14.38 ± 6.35
Estradiol (pmol/L) on day
of HCG admin
8354.51 ± 4171.09 8226.81 ± 5262.10
Estradiol (pmol/L) at HCG
admin/Mature egg
1296.84 ± 1154.87 935.25 ± 436.13
Progesterone (nmol/L) on
day of HCG admin
8.54 ± 4.23 6.87 ± 3.49
Endometrial thickness (mm)
on day of HCG admin
1.02 ± 0.27 1.04 ± 0.25
Both groups were comparable with regard to their baseline hormonal profile.moderate and no embryo transfer was done in these
cycles.
In contrast, when comparing the older women (groups
1-B and 2-B), we found that E2 levels on the day of hCG
administration were significantly higher while FSH levels
were lower on cycle day 7 (P = 0.027) and on day of hCG
administration (P = 0.037) in the group that used low
dose hCG [group 1-B]. When compared with group 2-B,
the number of mature eggs was higher (P = 0.019), theeatment groups
P Value Group 1-B r
FSH + Low dose





0.243 6.97 ± 2.1 7.42 ± 2.78 0.232
0.19 3.63 ± 2.02 4.37 ± 2.85 0.119
0.451 120.39 ± 105.46 123.84 ± 37.04 0.426
0.063 4.21 ± 2.07 5.57 ± 4.48 0.066
0.486 17.38 ± 4.93 19.96 ± 5.83 0.037
0.443 8692.51 ±4174.06 6858.54 ± 3461.78 0.027
0.025 1933.70 ± 1475.24 2214.41 ± 1946.52 0.265
0.016 7.59 ± 3.88 6.48 ± 2.38 0.081
0.336 0.98 ± 0.25 0.921± .026 0.125
Table 3 Cycle outcome measures
Group 1-A r





P Value Group 1-B r
FSH + Low dose





Starting dose of FSH 246.43±61.45 238.06±71.96 0.501 302.56±41.28 322.65±60.03 0.114
Total dose of FSH. 2,496±774 2,284±843 0.082 3,217±874 3,264±1,009 0.415
Treatment duration, days 10.02±1.73 9.45±1.48 0.064 10.03±1.58 9.40±1.90 0.072
Need for dose change 8/94 (8.5%) 12/67 (17.9%) 0.412 5/39 (12.8%) 4/32 (12.5%) 0.193
No of retrieved oocytes 10.83±6.55 12.50±7.29 0.10 7.92±4.32 6.28±4.50 0.067
No of mature eggs 9.49±5.78 10.37±6.55 0.230 5.72±3.52 4.00±3.34 0.019
No of fertilized eggs 6.71 ± 4.43 7.35 ± 4.35 0.227 4.89 ± 2.74 3.70 ± 2.09 0.027
Fertilization rate
per retrieved oocyte
61.47%± 18.38 62.97%± 21.39 0.347 58.96%± 19.48 58.72%± 33.48 0.394
No of Embryos per transfer 2.66 ± 1.22 2.68 ± 1.16 0.459 2.92 ± 1.09 3.00 ± 1.37 0.399
No of frozen embryos 2.90 ± 3.66 4.14 ± 4.62 0.128 1.03 ± 2.13 0.296± 0.95 0.033
Total pregnancies
per cycle started
12/49 (24.49%) 23/67 (34.33%) 0.416 6/39 (15.38%) 3/32 (9.38%) 0.090
Total pregnancies
per cycle completed
12/45 (26.67%) 23/60 (38.33%) 0.152 6/38 (15.79%) 3/27 (11.11%) 0.588
Cancelled cycles 3 2 0 4
Hyper stimulation 0 5 0 0
No eggs retrieved 1 0 1 1
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number of frozen embryos (0.033) was higher in group
1-B. (Table 3)
Overall, there were no differences in endometrial
thickness or fertilization rates in any of the groups. Preg-
nancy rates were not significantly different between
group 1-A and 2-A, and between 1-B and 2-B.
Cost analysis
The cost was determined using the average cost of a sin-
gle unit of recFSH which was approximately Canadian
$1.00 during this study. The cost-effectiveness ratio was
calculated by determining the average cost of the stimu-
lation protocol for each mature oocyte. The overall cost
of medications per cycle started was almost the same
but the cost/mature follicle was less in the low dose
hCG group in the women > 40 years of age (P = 0.053).
The average cost/mature follicle in group (1-B) was
$878.78 while in the FSH only group (2-B) it was
$1493.17.
Discussion
In this study we evaluated the effects of adding low dose
hCG to recFSH for ovarian stimulation in women under-
going IVF. We compared the outcome of this protocol
with patients of the same age who received recFSH
alone. The results showed that the combination of low
dose hCG and recFSH improved the outcome of IVF
cycles in the advanced age group by increasing thenumber of mature oocytes, the number of fertilized eggs
and reduced the cost/mature egg. We did not detect a
significant effect of addition of low dose hCG to the
group of younger women. Previous prospective rando-
mized studies showed that the addition of recLH to
recFSH improved the implantation and pregnancy rates
among older patients undergoing a long GnRH-agonist
down regulation protocol, in comparison to younger
patients. Therefore our finding that the older patients
seem to benefit more from the addition of hCG is con-
sistent with previous reports on recLH [4,17].
In natural cycles, follicular maturation and develop-
ment is a long, complex process beginning months be-
fore ovulation of a mature oocyte [18,19]. According to
the two cell theory, both FSH and LH are necessary for
folliculogenesis and ovulation. LH promotes the produc-
tion of androgens from cholesterol and pregnenolone by
stimulating 17-alpha-hydroxylase activity in theca cells.
Androgen diffuses to the granulosa cells where FSH
induces the expression of aromatase [20] to enable con-
version of androgens to estrogen [21] . In addition FSH
induces LH receptors on the granulosa cells of develop-
ing antral and preovulatory follicles [22].
For a selection of a single dominant follicle, LH pulses
are required for maintenance of theca enzymes to pro-
duce androgen substrate for aromatization, and LH may
also support the growth and maturation of larger folli-
cles through binding to specific granulosa cell LH recep-
tors that develop after FSH priming [23,24]. In a long
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through pituitary downregulation. The addition of daily
low dose hCG to recFSH during ovarian stimulation
may provide sufficient amounts of LH activity [25] to
improve treatment outcomes for patients with biologic-
ally older ovaries [26].
In a long GnRH agonist cycle, the lowest serum con-
centration of LH will be reached in the late follicular
phase. At this stage of folliculogenesis in natural cycles,
the mature follicles gradually transition their control to
LH by increasing the number of granulosa cell LH
receptors. Hence, several authors suggested that the late
follicular phase is the most appropriate time to add LH/
hCG to the stimulation as successfully reported by Fili-
cori et all [12]. On the other hand, hCG priming was
shown to increase testosterone production [27] which in
turn, will induce an increased expression of follicular
FSH receptors and greater sensitivity to stimulation. The
administration of hCG in the first four days of ovarian
stimulation resulted in a significant increase in the num-
ber of mature follicles, retrieved eggs, implantation and
pregnancy rate [11]. In the present study we decided to
combine the two approaches and provide hCG through-
out the FSH ovarian stimulation.
In none of the cycles included in the study did low
dose hCG administration cause premature luteinization.
Also, similar to our experience, an earlier study by Fili-
cori and colleagues showed that 200 IU of hCG is well
tolerated with no adverse effects detected in patients re-
ceiving this treatment [11].
The present study showed that serum FSH levels were
significantly lower on cycle day 7 and on the day of hCG
administration in the advanced age group that received
low dose hCG. A possible explanation for this observa-
tion might be the increased production of androgen by
theca cells under the effect of low dose hCG which in
turn increases the sensitivity of granulosa cells to utilize
FSH [23].
Despite the lack of a significant difference in pregnancy
rates between the hCG and control groups, the increased
number of frozen embryos in the older patients receiving
hCG (group 1-B) could potentially translate to a higher
overall cumulative pregnancy rate [28] .
We also have to mention that no cases of ovarian
hyperstimulation syndrome were recorded in patients
who received low dose hCG in addition to recFSH while
5 cases were recorded in recFSH only group. The same
was observed in other studies [29]. Potential explana-
tions include the promotion of growth of larger, mature
follicles only by the hCG and a decreased production of
endothelial growth factor (VEGF), which tends to be
secreted from the relatively smaller follicles [30]. VEGF
is known as an important factor in development of
OHSS.The main limitation of this study was its retrospective
design with the inherent problems related to selection
bias in the patients assigned to each treatment. While
we cannot correct for this problem, our data analysis
suggests that the patients in group 1 and group 2 were
comparable in all demographic parameters including age
and baseline FSH levels. We believe that our findings
provide preliminary evidence of a beneficial effect of low
dose hCG supplementation in recFSH stimulation in
older women undergoing IVF treatment, and should
serve as a basis for a future prospective randomized con-
trolled trial.
Conclusion
The addition of hCG to recFSH throughout the stimula-
tion in a long GnRH IVF protocol had only benefited
the group of patients 40 years and older. The recorded
benefits included a higher number of mature and ferti-
lized eggs and frozen embryos. While the cost per ma-
ture egg was lower.
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